The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol

NCT03563365 | Terminated Phase 4 FDA Drug

• 1 other identifier: TPX-PW3-2018-A
• Study Type: interventional
• Target: 43
• Locations: 1 country
• Sites: 1

Brief Summary

A Randomized, Investigator Blinded, Single Site, Three Arm Clinical Study to Assess the Functional and Emotional Benefits of Replenix Power of Three Cream with Resveratrol , Replenix Power of Three Cream with Resveratrol with Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, utilized to treat subjects with Facial Acne Vulgaris

Conditions

Acne Vulgaris

Outcome Measures

Primary Outcomes (7)

• Investigator Global Assessment (IGA)

  To assess the change in Acne Vulgaris on a scale of 1 to 4, where 1 represents clear skin and 4 represents severe acne, at each scheduled visit with the use of Replenix Power of three with Resveratrol.

  Screening, Baseline, Week 2, Week 4, Week 8, Week 12

• Subject Global Assessment (SGA)

  To assess the change in Acne Vulgaris on a scale of 1 to 5, where 1 represents a worsening of acne and 5 represents clearing of acne, at each scheduled visit as compared to baseline with the use of Replenix Power of three with Resveratrol.

  Screening, Baseline, Week 2, Week 4, Week 8, Week 12

• Subject Overall Assessment of Tone and Texture (SOATT)

  To assess the change on skin tone and texture on a scale of 1 to 7, where 1 represents worse tone and texture and 7 represents better tone and texture, at each scheduled visit with use of Replenix Power of three with Resveratrol.

  Screening, Baseline, Week 2, Week 4, Week 8, Week 12

• Investigator Overall Assessment of Tone and Texture (IOATT)

  To assess the change on skin tone and texture on a scale of 1 to 7, where 1 represents worse tone and texture and 7 represents better tone and texture, at each scheduled visit with use of Replenix Power of three with Resveratrol.

  Screening, Baseline, Week 2, Week 4, Week 8, Week 12

• Subject Assessment of Skin Dysesthesia (SDA)

  To assess the change in Dysesthesia on a scale of 1 to 7, where 1 represents no dysesthesia and 7 represents severe dysesthesia, at each scheduled visit with use of Replenix Power of three with Resveratrol.

  Screening, Baseline, Week 2, Week 4, Week 8, Week 12

• Subject Quality of Life (SQOL)

  To assess the change in Subject Quality of Life on a scale of 1 to 7, where 1 represents better quality of life and 7 represents worse quality of life, at Screening, Baseline and week 12 with use of Replenix Power of three with Resveratrol.

  Screening, Baseline, Week 12

• Local Tolerability Assessment

  To assess the change in Local Tolerability on a scale of 0 to 3, where 0 represents no tolerability issues and 3 represents severe tolerability issues, at each scheduled visit with use of Replenix Power of three with Resveratrol.

  Screening, Baseline, Week 2, Week 4, Week 8, Week 12

Study Arms (3)

Replenix

EXPERIMENTAL

Replenix power of 3 cream with Resveratrol applied twice daily

Other: Replenix Power of 3 Cream with resveratrol

Replenix and Adapalene and Benzoyl Peroxide gel

EXPERIMENTAL

Replenix power of 3 cream with Resveratrol applied twice daily and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily

Other: Replenix Power of 3 Cream with resveratrol; Drug: Adapalene and Benzoyl peroxide gel, 0.1%/2.5%

Adapalene and Benzoyl Peroxide gel

ACTIVE COMPARATOR

Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily

Drug: Adapalene and Benzoyl peroxide gel, 0.1%/2.5%

Interventions

Replenix Power of 3 Cream with resveratrol OTHER

Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids

Replenix; Replenix and Adapalene and Benzoyl Peroxide gel

Adapalene and Benzoyl peroxide gel, 0.1%/2.5% DRUG

FDA approved topical agent for the treatment of acne

Adapalene and Benzoyl Peroxide gel; Replenix and Adapalene and Benzoyl Peroxide gel

Eligibility Criteria

• Age: 12 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of Acne vulgaris
• On the face, ≥ 20 non-inflammatory lesions (i.e., open and closed comedones) AND \< 75 inflammatory lesions (i.e., papules and pustules) AND ≤ 1 nodulocystic lesions (i.e., nodules and cysts).
• Investigator's Global Assessment (IGA) of acne severity grade 2 or 3
• Subject must be able to follow study instructions and likely to complete all required visits, as assessed by the Investigator.
• Subject/Guardian must sign an IRB-approved Informed Consent/Assent/Assent Form including photography consent, and the Authorization for Use and release of Health and Research Study Information (HIPAA) form prior to any study-related procedures being performed

You may not qualify if:

• Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).
• Subjects who have acne conglobata, acne fulminans and secondary acne (e.g.:
• chloracne and drug induced acne).
• Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris. Well trimmed moustaches are allowed.
• History of hypersensitivity or allergy to benzoyl peroxide or adapalene and or any of the study product ingredients.
• Subjects who have a severe or intense irritation on the face.
• Use within 6 months prior to baseline (Randomization) of oral retinoids (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
• Use for less than 3 months prior to baseline (Randomization) of estrogens or oral contraceptives; use of such therapy is allowed if it will remain constant throughout the study.
• Use on the face within 1 month prior to baseline (Randomization) or during the study of: 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.
• Use within 1 month prior to baseline (Randomization) of: 1) spironolactone, 2) systemic steroids, 3) systemic antibiotics, 4) systemic treatment for acne vulgaris (other than oralretinoids, which require a 6-month washout), or 5) systemic anti- inflammatory agents.
• Use within 2 weeks prior to baseline (Randomization) of: 1) topical steroids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparations, 4) topical anti-inflammatory agents, 5) medicated cleansers or 6) topical antibiotics.
• Subjects who have had general anesthesia for any reason and patients who have received neuromuscular blocking agents within 14 days prior to study entry (Randomization).
• Concomitant use of facial product containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or α- or β-hydroxy acids.
• Concomitant use of mega-doses of certain vitamins (such as vitamin D and vitamin B12), haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.
• Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2 weeks or during the study.

Sponsors & Collaborators

• Yardley Dermatology Associates: lead
• Topix Pharmaceuticals, Inc: collaborator

Study Sites (1)

Yardley Dermatology Associates, PC

Yardley, Pennsylvania, 19067, United States

Location

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Resveratrol; Adapalene

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

Stilbestrols; Stilbenes; Benzylidene Compounds; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polyphenols; Phenols; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds

Study Officials

• Richard G Fried, MD, PhD

  Yardley Dermatology Associates, PC

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Masking Details: Subject is instructed not to discuss or disclose treatment arm with PI.
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator/ Clinical Director

Study Record Dates

• First Submitted: May 23, 2018
• First Posted: June 20, 2018
• Study Start: June 4, 2018
• Primary Completion: March 2, 2021
• Study Completion: March 2, 2021
• Last Updated: April 23, 2021

Record last verified: 2021-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)